Health Care Equipment & Services

Insider sales of Ensign Group’s shares show disciplined tax‑cover trading, not a sell‑off, and suggest the company’s bullish momentum will likely stay strong.

CEO Kathy Lee‑Sepsick’s massive RSU buy signals strong confidence in Femasys’s future, driving investor optimism amid new Swiss partnerships and a 6.6% share gain.

Explore how Quest Diagnostics’ executive Patrick Plewman’s RSU grants and tax‑efficient sales reveal insider confidence and liquidity strategy in the health‑care diagnostics market.

Ensign Group’s legal chief buys shares, signaling insider confidence as the stock surges—investors see a bullish insider endorsement.

Insider buying at Bausch + Lomb signals renewed confidence: Munsch Frederick’s purchase follows a July sale, suggesting executives see long‑term value beyond current earnings volatility.

COO’s purchase of 8,824 Tivic Health shares signals management confidence, hinting at future upside amid a BARDA partnership and steep stock decline.

CEO Robert Mauch sells 1,333 shares of Cencora stock a day after the $3.5 B Covetrus merger, indicating routine liquidity management amid a promising veterinary tech expansion.

CEO Jeff Shaner’s 119,884‑share sale at $7.65 on Feb. 17, 2026 reflects a routine tax‑triggered vesting move, not a strategic exit, but raises questions on Aveanna’s outlook.

Insider buying at HeartFlow signals confidence—executives purchase shares far below market price ahead of earnings, hinting at a potential upside if results beat expectations.

Insider sale at Hinge Health: Robinson Elliott’s February 2026 sell‑off is a routine liquidity move amid a bullish rally, not a confidence signal.